Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43414 | 0.88 | POLB (0.41) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL8816003 | 0.87 | POLB (0.60) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL30498662 | 0.81 | ALDH1A1 (0.56) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL277974 | 0.81 | ALDH1A1 (0.56) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL2435515 | 0.81 | POLB (0.41) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL20983700 | 0.80 | ALDH1A1 (0.50) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL4405681 | 0.78 | GCK (0.40) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL29130297 | 0.78 | ALDH1A1 (0.48) | POLBALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL465750 | 0.77 | LMNA (0.37) | POLBALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL499428 | 0.77 | KMT2A (0.46) | ALDH1A1SMN1; SMN2HPGDKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931418-B2 | Methods of treating severe inflammation | Ashvattha Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11918657-B2 | Dendrimer delivery system and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044776-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044756-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044760-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240058459-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4322961-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024020597-A1 | DENDRIMER-ENABLED TARGETED INTRACELLULAR CRISPR/CAS SYSTEM DELIVERY AND GENE EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230398241-A1 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | Ashvattha Therapeutics, Inc. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| EP-2311436-A1 | Stabilized protein crystals, formulations containing them and methods of making them | Altus Pharmaceuticals Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7872103-B2 | Modulating immune responses | CELLTECH R & D, LIMITED (GB) | 2011-01-18 | — | — | US | disclosed |
| EP-2267122-A1 | Controlled dissolution crosslinked protein crystals | Altus Pharmaceuticals Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258724-A1 | Modulating immune responses using multimerized anti-CD83 antibodies | Celltech R & D, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100249380-A1 | Modulating Immune Responses | CELLTECH R&D LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-7459155-B2 | Treating abdominal pain due to pancreatitis with seaprose | ALTUS PHARMACEUTICALS INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1985699-A1 | Controlled dissolution crosslinked protein crystals | Altus Pharmaceuticals Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20060002924-A1 | Conjugate of notch signalling pathway modulators and their use in medical treatment | CELLDEX THERAPEUTICS LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| US-20050158299-A1 | Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain | ELI LILLY AND COMPANY | 2005-07-21 | — | — | US | disclosed |
| WO-2004060262-A2 | MODULATORS OF NOTCH SIGNALLING FOR USE IN IMMUNOTHERPAPY | LORANTIS LIMITED (GB) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398241-A1 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | ESRRG, CD47, CD68 | POLB 4588/4885ALDH1A1 3122/4885MAPT 1457/4885 |
| US-11918657-B2 | Dendrimer delivery system and methods of use thereof | TLR3, CD40LG, OXGR1 | POLB 4378/4885ALDH1A1 2712/4885MAPT 1292/4885 |
| US-20240058459-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | FLT4, KDR, FLT1 | POLB 4778/4885ALDH1A1 2726/4885MAPT 1286/4885 |
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | POLB 797/4885ALDH1A1 3164/4885MAPT 3762/4885 |
| US-20060002924-A1 | Conjugate of notch signalling pathway modulators and their use in medical treatment | NOTCH2, NOTCH1, NOTCH4 | POLB 4361/4885ALDH1A1 2966/4885MAPT 1559/4885 |
| US-11931418-B2 | Methods of treating severe inflammation | TLR9, TLR3, IL6 | POLB 2208/4885ALDH1A1 2386/4885MAPT 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.